Previous 10 | Next 10 |
– A Prespecified, Exploratory Analysis of Participants Reports Those with Higher Baseline Inflammation More Likely to Experience a Major Cardiovascular Event (MACE), Cardiovascular Death, and All-Cause Mortality Compared to Those with the Lowest Inflammation – ȁ...
2023-11-12 22:45:00 ET Summary Esperion Therapeutics reports strong Q3 earnings for bempedoic acid, with revenues of $20.3M and impressive growth in retail Rx and new-to-brand prescriptions. Anticipated label expansion in the US and EU in 2024 could significantly broaden bempedoic...
– Data from Randomized Control Trial Will Advance Evidence for Evaluation and Treatment of Heart Disease by Studying Actual Disease: Atherosclerosis – ANN ARBOR, Mich., Nov. 11, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced participation in the TRANSFORM trial at ...
2023-11-07 13:30:05 ET Esperion Therapeutics, Inc. (ESPR) Q3 2023 Earnings Conference Call November 07, 2023 08:00 AM ET Company Participants Alexis Callahan - Head of Investor Relations Sheldon Koenig - President & Chief Executive Officer Ben Halladay - Chie...
2023-11-07 06:03:41 ET More on Esperion Therapeutics Esperion Therapeutics: Speculative Buy, Playing The $300 Million Milestone Litigation Esperion gains on new data for cholesterol-lowering agent Seeking Alpha’s Quant Rating on Esperion Therapeutics H...
Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
– Q3 U.S. Net Product Revenue Grew 45% Y/Y to $20.3 Million; Q3 Total Revenue Grew 79% Y/Y to $34.0 Million – – Q3 Retail Prescription Equivalents Grew 33% Y/Y and 8% Q/Q, Demonstrating Sustained Momentum into 2H 2023 – – Received FDA Acceptanc...
Esperion Therapeutics Inc. (ESPR) is expected to report $-0.42 for Q3 2023
2023-11-06 15:15:50 ET More on Esperion Therapeutics Esperion Therapeutics: Speculative Buy, Playing The $300 Million Milestone Litigation Esperion gains on new data for cholesterol-lowering agent Seeking Alpha’s Quant Rating on Esperion Therapeutics H...
ANN ARBOR, Mich., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report third quarter 2023 financial results before the market opens on Tuesday, November 7, 2023. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these finan...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
– OMERS Life Sciences to Purchase Esperion’s European Royalty on Bempedoic Acid Products for $304.7 Million with European Royalties Reverting to Esperion Once OMERS Receives 1.7 Times its Investment – – Esperion Retains Rights to Receive all Poten...